Genomic landscape and clinical impact of BRCA1/2 pathogenic variants in metastatic castration-resistant prostate cancer - PubMed
4 hours ago
- #BRCA1/2
- #PARP inhibitors
- #mCRPC
- PARP inhibitors benefit mCRPC patients with BRCA1/2 pathogenic variants.
- Study of 5893 mCRPC patients in Japan: 2203 had HRR gene alterations, 792 had BRCA1/2 variants.
- Olaparib recommended for BRCA1/2 variant carriers; 389 received treatment.
- HRR gene alterations linked to shorter overall survival (OS).
- BRCA1 variants associated with worse OS than BRCA2 in olaparib-treated patients.
- BRCA2 loss correlated with the most favorable OS in BRCA2-altered cases.
- Multivariate analysis confirmed BRCA1 as an adverse and BRCA2 loss as a favorable prognostic factor in olaparib-treated patients.
- Findings emphasize the need for detailed genomic annotation in mCRPC precision oncology.